Psilocybin can be produced de novo in yeast. The findings could help with the development of drugs that utilize the psychedelic compound to treat depression and other mental health disorders.
Researchers explore why using hallucinogens to treat an array of mental health disorders is becoming more popular.
Months after receiving psilocybin treatments for depression, patients report feeling more connected with nature and experience a shift away from authoritarian political views, researchers report.
A new study reports people who have used a classic psychedelic are significantly less likely to commit a crime or indulge in criminal behavior. However, use of other controlled substances is linked to an increased risk of criminal behavior, researchers report.
A new study adds to growing evidence supporting the benefits of psychedelics to treat mental illnesses. Researchers report psilocybin, the psychoactive compound in magic mushrooms, is effective in reducing symptoms for people with treatment resistant depression. The study reveals the compound resets the activity of a brain network associated with depression, helping to improve symptoms in patients for up to 5 weeks following treatment.
According to researchers, a single large dose if psilocybin, the active hallucinogenic compound found in magic mushrooms, helped provide relief for people suffering from cancer related depression and anxiety for up to six months.
In a new study, researchers report on the potential for using psilocybin, a hallucinogenic compound derived from magic mushrooms, for treating patients with treatment resistant depression.
Study suggests that a single dose of psilocybin, the active ingredient of magic mushrooms, may be enough to produce a lasting decrease in depression and anxiety for cancer patients.
Brain scans of people under the influence of the psilocybin, the active ingredient in magic mushrooms, have given scientists the...